GlassScriptPhysician profile
Edward B Decker
NPI 1942243829
$5,099.68
in general payments reported to CMS, 2019-2025
26 companies · $987 in 2025
The $987 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,404 · 2020: $707 · 2021: $429 · 2022: $543 · 2023: $644 · 2024: $386 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,553.09 | 2019-2022 | |
| Abbvie INC. | $731.59 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Alcon Vision LLC | $416.88 | 2019-2025 | Clareon Panoptix Pro, Tryptyr, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $373.02 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Sun Pharmaceutical Industries INC. | $291.57 | 2019-2025 | Cequa |
| Sight Sciences, INC. | $255.54 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $224.69 | 2020-2025 | Idose |
| Tarsus Pharmaceuticals, INC. | $191.85 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $189.96 | 2022-2025 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $156.56 | 2019-2023 | Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.91 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $112.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $80.06 | 2019-2022 | |
| Carl Zeiss Meditec, INC. | $66.72 | 2019 | |
| Eyevance Pharmaceuticals LLC | $58.72 | 2022-2023 | Flarex |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $56.36 | 2020-2024 | Dextenza |
| Kala Pharmaceuticals, INC. | $55.35 | 2021-2022 | |
| Lundbeck LLC | $29.18 | 2019 | |
| Therapeuticsmd, INC. | $26.04 | 2019 | |
| Biotissue Holdings INC. | $22.40 | 2025 | |
| Mallinckrodt Hospital Products INC. | $16.26 | 2023 | Acthar |
| Adamas Pharmaceuticals, INC. | $15.79 | 2019 | |
| Dompe US, INC. | $15.06 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.79 | 2022 | |
| Shire North American Group INC | $14.78 | 2019 | |
| Harrow Eye, LLC | $14.63 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Decker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.